Compass Therapeutics (NASDAQ:CMPX) Cut to “Market Perform” at Leerink Partners

Compass Therapeutics (NASDAQ:CMPX) was downgraded by investment analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a research note issued to investors on Friday, Marketbeat reports. They presently have a $4.00 price objective on the stock, down from their previous price objective of $5.00. Leerink Partners’ target price points to a potential upside of 151.57% from the stock’s current price.

Other analysts also recently issued research reports about the company. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, August 7th. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a report on Monday, September 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research note on Monday.

Compass Therapeutics Stock Performance

CMPX opened at $1.59 on Friday. The stock has a market capitalization of $218.77 million, a price-to-earnings ratio of -4.30 and a beta of 0.92. The company has a fifty day moving average of $1.76 and a 200 day moving average of $1.42. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. On average, equities research analysts forecast that Compass Therapeutics will post -0.42 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors have recently modified their holdings of CMPX. Bleakley Financial Group LLC purchased a new stake in Compass Therapeutics during the 1st quarter valued at $80,000. Renaissance Technologies LLC increased its position in Compass Therapeutics by 99.7% during the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after acquiring an additional 70,200 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Compass Therapeutics by 10.3% in the second quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after acquiring an additional 12,315 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Compass Therapeutics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock worth $8,221,000 after acquiring an additional 71,008 shares during the last quarter. Finally, Panagora Asset Management Inc. purchased a new position in shares of Compass Therapeutics during the 2nd quarter worth about $68,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.